Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Kazuhiko Koike

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9787-1907; OpenAlex author ID A5046522736. Sources: OpenAlex.

Their work

Papers
62 (first author 0, last author 48)
Trials
0
Grants
0
Labs led
1
Collaborators
95
Papers, trials and grants by year

2011: 5 papers · 2012: 6 papers · 2013: 10 papers · 2014: 8 papers · 2015: 3 papers · 2016: 4 papers · 2017: 3 papers · 2018: 3 papers · 2019: 6 papers · 2020: 3 papers · 2021: 6 papers · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers

Papers 50 of 62

  1. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. Co-author DOI 10.1016/j.jbc.2024.105742↗
  2. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002291↗
  3. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Last author DOI 10.1016/j.isci.2023.106021↗
  4. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors. Co-author DOI 10.1016/j.omto.2022.12.001↗
  5. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  6. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Last author DOI 10.1007/s10637-020-00982-7↗
  7. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Last author DOI 10.1007/s10637-020-01022-0↗
  8. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A… Co-author DOI 10.1016/j.clnu.2021.06.011↗
  9. Aberrant expression of a novel circular RNA in pancreatic cancer. Last author DOI 10.1038/s10038-020-00826-5↗
  10. [A case of advanced pancreatic cancer with oculomotor nerve palsy caused by herpes zoster after introduction of gemcitabine plus nab-paclitaxel]. Co-author DOI 10.11405/nisshoshi.118.86↗
  11. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… Last author DOI 10.5009/gnl19302↗
  12. The biological role of metabolic reprogramming in pancreatic cancer. Last author DOI 10.1002/mco2.37↗
  13. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Last author DOI 10.1038/s41598-020-78320-3↗
  14. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Last author DOI 10.3390/diagnostics10080572↗
  15. The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients. Co-author DOI 10.1007/s00280-019-03895-2↗
  16. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Last author DOI 10.1007/s10637-018-0691-9↗
  17. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Last author DOI 10.1016/j.pan.2019.07.002↗
  18. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… Last author DOI 10.1038/s41389-018-0117-8↗
  19. Brain metastasis in pancreatic cancer: Two case reports. Last author DOI 10.1097/md.0000000000014227↗
  20. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Co-author DOI 10.4103/sjg.sjg_56_19↗
  21. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Last author DOI 10.1007/s12032-018-1158-8↗
  22. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001079↗
  23. Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-18-0139↗
  24. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. Co-author DOI 10.1007/s00330-017-4895-8↗
  25. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Last author DOI 10.1097/mpa.0000000000000767↗
  26. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Last author DOI 10.1097/mpa.0000000000000889↗
  27. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Last author DOI 10.1007/s10637-016-0369-0↗
  28. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Last author DOI 10.1016/j.ejca.2016.05.016↗
  29. Quantitation of circulating satellite RNAs in pancreatic cancer patients. Last author DOI 10.1172/jci.insight.86646↗
  30. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Last author DOI 10.18632/oncotarget.11129↗
  31. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Last author DOI 10.1007/s00432-014-1873-2↗
  32. Pancreatic cancer with malignant ascites: clinical features and outcomes. Last author DOI 10.1097/mpa.0000000000000290↗
  33. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Last author DOI 10.11405/nisshoshi.112.1474↗
  34. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Co-author DOI 10.1002/jhbp.130↗
  35. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Last author DOI 10.1007/s00280-014-2563-0↗
  36. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Last author DOI 10.1007/s12029-014-9603-1↗
  37. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Last author DOI 10.1038/bjc.2014.131↗
  38. Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα. Last author DOI 10.1093/carcin/bgu136↗
  39. A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Last author DOI 10.1097/mpa.0000000000000139↗
  40. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Last author DOI 10.1097/mpa.0000000000000158↗
  41. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Last author DOI 10.1111/jgh.12602↗
  42. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Last author DOI 10.1007/s00280-012-1981-0↗
  43. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Last author DOI 10.1007/s00280-013-2278-7↗
  44. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Last author DOI 10.1007/s00280-013-2313-8↗
  45. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Last author DOI 10.1007/s00535-012-0622-z↗
  46. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Last author DOI 10.1007/s10637-013-9972-5↗
  47. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Last author DOI 10.1016/j.pan.2013.03.013↗
  48. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Last author DOI 10.1097/mpa.0b013e31825de678↗
  49. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Last author DOI 10.1097/mpa.0b013e318270ea97↗
  50. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Last author DOI 10.1111/cas.12080↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 48 shared papers, 2011–2024 · strength 2.71
  2. Hiroyuki Isayama · 46 shared papers, 2011–2021 · strength 2.15
  3. Hideaki Ijichi · 32 shared papers, 2011–2024 · strength 1.83
  4. Suguru Mizuno · 31 shared papers, 2011–2021 · strength 1.48
  5. Hirofumi Kogure · 33 shared papers, 2011–2021 · strength 1.45
  6. Naminatsu Takahara · 25 shared papers, 2011–2021 · strength 1.22
  7. Minoru Tada · 32 shared papers, 2011–2019 · strength 1.18
  8. Tsuyoshi Hamada · 23 shared papers, 2011–2022 · strength 1.17
  9. Kei Saito · 15 shared papers, 2014–2021 · strength 1.10
  10. Kazunaga Ishigaki · 12 shared papers, 2015–2023 · strength 0.98
  11. Motoyuki Otsuka · 7 shared papers, 2014–2024 · strength 0.76
  12. Koji Miyabayashi · 21 shared papers, 2011–2020 · strength 0.76
  13. Takahiro Kishikawa · 7 shared papers, 2015–2024 · strength 0.71
  14. Naoki Sasahira · 19 shared papers, 2011–2022 · strength 0.69
  15. Takahiro Seimiya · 5 shared papers, 2018–2024 · strength 0.67
  16. Tatsunori Suzuki · 5 shared papers, 2018–2024 · strength 0.65
  17. Tomotaka Saito · 9 shared papers, 2014–2021 · strength 0.63
  18. Dai Mohri · 17 shared papers, 2011–2020 · strength 0.59
  19. Takuma Iwata · 4 shared papers, 2020–2024 · strength 0.59
  20. Saburo Matsubara · 14 shared papers, 2011–2019 · strength 0.57
  21. Keisuke Yamamoto · 15 shared papers, 2011–2020 · strength 0.55
  22. Takashi Sasaki · 18 shared papers, 2011–2015 · strength 0.55
  23. Mitsuhiro Fujishiro · 4 shared papers, 2011–2024 · strength 0.52
  24. Chikako Shibata · 3 shared papers, 2021–2024 · strength 0.45
  25. Kazumichi Kawakubo · 12 shared papers, 2011–2021 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.